Hhcepo-CV Dry Syrup is a combination antibiotic formulation containing Cefpodoxime Proxetil 50 mg and Clavulanic Acid 31.25 mg per 5 ml reconstituted suspension. Cefpodoxime Proxetil, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effective against a wide range of Gram-positive and Gram-negative pathogens. Clavulanic Acid, a beta-lactamase inhibitor, enhances the efficacy of Cefpodoxime by preventing enzymatic degradation of the antibiotic, thereby extending its spectrum to beta-lactamase producing resistant strains. This synergistic combination is indicated for the treatment of various bacterial infections including respiratory tract infections (such as bronchitis, pneumonia), urinary tract infections, skin and soft tissue infections, and otitis media. Hhcepo-CV Dry Syrup is particularly useful in pediatric patients due to its palatable formulation and ease of administration. The dosage should be individualized based on the severity of infection and patient weight, with adherence to prescribed duration to prevent resistance development. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Use with caution in patients with a history of hypersensitivity to cephalosporins or penicillins. Proper reconstitution and storage conditions are essential to maintain stability and therapeutic efficacy.